Transvaginal surgical management of cesarean scar pregnancy: analysis of 49 cases from one tertiary care center

ObjectiveTo investigate the safety and effectiveness of transvaginal surgical management of cesarean scar pregnancy (CSP).Study designRetrospective analysis of 49 CSP patients who received transvaginal surgery in our hospital between December 2009 and April 2013. Patients were divided into two groups. Group A (30 patients) was defined as patients who had not received any treatment before transvaginal surgical management. Group B (19 patients) referred to patients who had received any previous treatment. Preoperative, intraoperative and postoperative data of both groups were collected and analyzed retrospectively.ResultsPreoperative serum β-hCG level, preoperative hemoglobin level and average serum β-hCG resolution time of group A and group B were 53,458.50 (36,382.00-94,100.50) versus 9779.00 (932.50-29623.00) U/l, 123.87 ± 10.95 versus 109.94 ± 16.05 g/l and 3.55 ± 1.81 versus 1.83 ± 1.15 weeks (P < 0.05). Vaginal bleeding and gestational age in group A were significantly lower than in group B, 2.5 (0.50-11.00) versus 15.00 (3.50-31.50) days and 52.50 (46.50-56.70) versus 60.00 (48.00-90.00) days, respectively (P < 0.05). The operative time, estimated blood loss, postoperative hospital stay, hospitalization expenses and menstruation recovery time of group A and group B were 56.61 ± 24.40 versus 67.56 ± 43.52 min, 45.65 ± 27.83 versus 76.67 ± 50.87 ml, 5.10 ± 2.89 versus 5.33 ± 3.99 days, 9001.94 ± 1848.37 versus 11,032.33 ± 5534.14 RMB and 1.16 ± 0.47 versus 1.26 ± 0.63 month respectively, which were similar between the two groups (P > 0.05). The intraoperative complication rate in group A was significantly lower than group B, 0 (0/30) versus 21.05% (4/19) (P < 0.05). The postoperative complication rate and total complication rate in group A and group B were 10.00% (3/30) versus 21.05% (4/19) and 10.00% (3/30) versus 31.58% (6/19) (P > 0.05), respectively.ConclusionTransvaginal surgery is an effective and relatively safe treatment option for CSP patients.